Literature DB >> 8906749

Inhibition of human B cell activation by gold compounds.

S Hirohata1.   

Abstract

The mechanism of action of gold compounds, which are effective in the treatment of rheumatoid arthritis (RA), has not been clearly identified. Although one of the characteristic features of RA is chronic stimulation of B cells, the effects of gold compounds on B cells have not been precisely assessed. We therefore examined the effects of gold sodium thiomalate (GST) on human B cells. IgM production was induced from highly purified B cells obtained from healthy donors by stimulation with Staphylococcus aureus Cowan 1 (SA) plus IL-2. T cell proliferation and IFN-gamma production were induced from highly purified T cells by stimulation with immobilized mAb to CD3. As little as 0.1 microg/ml (0.25 microM) GST almost completely suppressed B cell IgM production, whereas it did not suppress T cell proliferation or IFN-gamma production. The inhibition of IgM production by GST is not due to its thiomalate, but is most likely due to its gold components, since thiomalate alone did not inhibit IgM production. GST was required at the initiation of cultures to exert optimal suppressive effects on IgM production. Moreover, GST suppressed the expression of IL-2R (CD25) and transferrin receptor (CD71) on SA-stimulated B cells. These results indicate that GST preferentially inhibits the function of B cells at concentrations much lower than those which inhibit the function of T cells by interfering with the initial activation of B cells. The direct inhibitory effects of GST on human B cell activation described here may contribute at least in part to its therapeutic effect in RA.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8906749     DOI: 10.1006/clin.1996.0174

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  1 in total

1.  Gold concentrations in abiotic materials, plants, and animals: a synoptic review.

Authors:  R Eisler
Journal:  Environ Monit Assess       Date:  2004-01       Impact factor: 2.513

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.